Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

The Lancet Neurology - Tập 18 - Trang 428-438 - 2019
Magdy Selim1,2, Lydia D Foster3, Claudia S Moy4, Guohua Xi5, Michael D Hill6, Lewis B Morgenstern7, Steven M Greenberg2,8, Michael L James9, Vineeta Singh10, Wayne M Clark11, Casey Norton1, Yuko Y Palesch3, Sharon D Yeatts3
1Beth Israel Deaconess Medical Center, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
3Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
4National Institute of Neurological Disorders and Stroke, Bethesda, MD USA
5Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA
6Health Science Center, University of Calgary, Calgary, AB, Canada
7Department of Neurology, University of Michigan Medical School, Ann Arbor, MI USA
8Massachusetts General Hospital, Boston, MA, USA
9Department of Anesthesiology and Neurology, Duke University, Durham, NC, USA
10San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA
11Oregon Health and Science University Hospital, Portland, OR, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Neurology

Tập 18

428-438

Thông tin tác giả